Free Trial
NASDAQ:ZBIO

Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Zenas BioPharma logo
$9.31 -0.37 (-3.82%)
As of 06/18/2025 04:00 PM Eastern

About Zenas BioPharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$9.10
$9.76
50-Day Range
$6.78
$12.11
52-Week Range
$5.83
$26.25
Volume
130,927 shs
Average Volume
192,489 shs
Market Capitalization
$389.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.67
Consensus Rating
Buy

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zenas BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

ZBIO MarketRank™: 

Zenas BioPharma scored higher than 30% of companies evaluated by MarketBeat, and ranked 782nd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zenas BioPharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Zenas BioPharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zenas BioPharma is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zenas BioPharma is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zenas BioPharma has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zenas BioPharma's valuation and earnings.
  • Short Interest

    There is no current short interest data available for ZBIO.
  • Dividend Yield

    Zenas BioPharma does not currently pay a dividend.

  • Dividend Growth

    Zenas BioPharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ZBIO.
  • News Sentiment

    Zenas BioPharma has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Zenas BioPharma this week, compared to 15 articles on an average week.
  • Search Interest

    Only 1 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Zenas BioPharma's insider trading history.
Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

ZBIO Stock News Headlines

Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas BioPharma's stock was trading at $7.90 on January 1st, 2025. Since then, ZBIO shares have increased by 17.8% and is now trading at $9.31.
View the best growth stocks for 2025 here
.

Zenas BioPharma, Inc. (NASDAQ:ZBIO) released its earnings results on Thursday, May, 15th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The business earned $10 million during the quarter, compared to analyst estimates of $5 million.

Zenas BioPharma (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

Top institutional investors of Zenas BioPharma include Wellington Management Group LLP (2.09%), Charles Schwab Investment Management Inc. (0.28%), Jefferies Financial Group Inc. (0.11%) and Nuveen LLC (0.08%).

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Company Calendar

Last Earnings
5/15/2025
Today
6/18/2025
Next Earnings (Estimated)
8/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.67
High Stock Price Target
$45.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+293.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5 million
Price / Cash Flow
N/A
Book Value
$7.48 per share
Price / Book
1.24

Miscellaneous

Free Float
34,931,000
Market Cap
$389.44 million
Optionable
N/A
Beta
N/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 6/19/2025 by MarketBeat.com Staff
From Our Partners